The partnership includes support for the design of the Phase III trial and assistance in securing external funding.

UK pharma major GSK today revealed that it has licensed its Shigella vaccine candidate, altSonflex1-2-3, to India’s Bharat ...

GSK has licensed its shigella vaccine candidate to Bharat Biotech. The Big Pharma, which has vowed to help Bharat with trial ...

Hyderabad: Vaccine maker Bharat Biotech International Limited (BBIL) has in-licensed pharma giant GSK's under development ...

Under terms of the deal, Bharat Biotech will lead late-stage development and scale-up of the altSonflex1-2-3 Shigella vaccine ...

This collaboration reflects Bharat Biotech’s continued commitment to global public health and equitable vaccine access ...

Thanks to lab-grown miniature intestines, researchers at the Helmholtz Institute for RNA-based Infection Research (HIRI) in ...

Bharat Biotech has partnered with GSK to develop a Shigellosis vaccine. The altSonflex1-2-3 candidate is one of the most ...

Bharat Biotech joins GSK to develop a Shigella vaccine to fight shigellosis in children, with Phase 3 trials underway and ...

Hyderabad-based Bharat Biotech will lead Phase 3 trials, regulatory progress and manufacturing for Shigella vaccine ...

Bharat Biotech on Thursday said it has partnered with GSK plc for the development of a vaccine for Shigellosis, a severe form ...

Bharat Biotech has in-licensed GSK's Shigella vaccine candidate, altSonflex1-2-3, aimed at combating Shigellosis in young ...